Gland Pharma Limited (GLAND)
Healthcare · Pharmaceuticals & Biotechnology · NSE
· Updated 15 July 2026
₹2,488.3
↑ 31.25% (1Y)
🎯 Key Takeaways
- Revenue declined 1.5% QoQ to ₹1,384 in Q3FY25.
Market Cap
₹30,781
P/E Ratio
43.7
Div Yield
0.00%
Promoter
0.0%
📊 Quarterly Results (₹ Cr)
| Metric | Q4FY23 | Q1FY24 | Q2FY24 | Q3FY24 | Q4FY24 | Q1FY25 | Q2FY25 | Q3FY25 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 785 | 1,209 | 1,373 | 1,545 | 1,537 | 1,402 | 1,406 | 1,384 |
| Operating Profit | 151 | 332 | 377 | 394 | 401 | 316 | 357 | 418 |
| OPM % | 21.4% | 24.3% | 23.6% | 23.1% | 23.3% | 18.9% | 21.1% | 26.0% |
| Net Profit | 79 | 194 | 194 | 192 | 192 | 144 | 164 | 205 |
| EPS | ₹4.78 | ₹11.79 | ₹11.78 | ₹11.65 | ₹11.68 | ₹8.73 | ₹9.93 | ₹12.42 |
⚖️ Peer Comparison — Pharmaceuticals & Biotechnology
| Company | MCap (₹ Cr) | P/E | ROCE | ROE | D/E |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | 4.51 L Cr | 41.3 | 20.3% | 15.1% | 0.03 |
| Divi's Laboratories Limited | 1.79 L Cr | 72.4 | 22.1% | 16.6% | 0.00 |
| Torrent Pharmaceuticals Limited | 1.49 L Cr | 80.1 | — | — | — |
| Cipla Limited | 1.16 L Cr | 25.4 | 19.4% | 14.6% | 0.00 |
| Dr. Reddy's Laboratories Limited | 1.12 L Cr | 20.0 | 19.7% | 16.6% | 0.12 |
| Lupin Limited | 1.04 L Cr | 36.2 | — | — | — |
| Mankind Pharma Limited | 1.03 L Cr | 49.2 | — | — | — |
| Zydus Lifesciences Limited | 1.02 L Cr | 22.5 | — | — | — |
| Aurobindo Pharma Limited | 87,806 | 25.3 | — | — | — |
| Laurus Labs Limited | 71,455 | 356.8 | — | — | — |
🔗 Peer Stock Analyses
📋 Recent Filings
-
Financial Results 26 June 2026Gland Pharma announced that its trading window will close on June 27, 2026, ahead of the unaudited quarterly results for the quarter ending June 30, 2...
-
Announcement 22 June 2026Gland Pharma announced its schedule for upcoming analyst and institutional investor meetings, including one-on-one sessions with Ambit PMS arranged by...
-
🟡 voting results 18 June 2026Gland Pharma Limited's shareholders approved the reappointment of Udo Jahannes Vetter as Independent Director for a second term and William Robert Kel...
-
Announcement 17 June 2026Gland Pharma announced a schedule of analyst and institutional investor meetings, including a one-on-one session with SiMPL PMS on June 22, 2026, arra...
-
🟡 Board Meeting 16 June 2026Gland Pharma disclosed that independent director Satyanarayana Murthy Chavali resigned effective June 15, 2026, citing a potential conflict of interes...
-
Announcement 16 June 2026Gland Pharma announced its upcoming analyst and institutional investor meeting schedule, listing one-on-one sessions with ICICI Prudential AMC, Jeffer...
-
🟡 Board Meeting 15 June 2026The board reappointed Udo Jahannes Vetter as Independent Director for a second term until 2031 and appointed William Robert Keller as an Additional Di...
-
🟡 Board Meeting 15 June 2026No summary available
-
🟡 Board Meeting 15 June 2026Gland Pharma announced board changes effective June 15, 2026, reappointing Udo Jahannes Vetter as Independent Director for five years until 2031, appo...
-
Announcement 4 June 2026Gland Pharma announced its schedule of upcoming analyst and institutional investor meetings, listing one-on-one sessions with Haitong Securities, ICIC...
Read the full analysis
Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.
Sign Up Free — Unlock Full Analysis2 free AI queries per day.
Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-07-15.
📡 Get AI alerts when GLAND files new disclosures
Track GLAND filings, board meetings, and corporate actions. Free email alerts at 5 PM.
Track GLAND — FreeFree account · 2 AI queries/day
© 2026 StockFin.ai — AI-powered Indian stock research